{"id":161,"date":"2024-02-21T12:14:13","date_gmt":"2024-02-21T10:14:13","guid":{"rendered":"https:\/\/webs.uab.cat\/therCNS\/?page_id=161"},"modified":"2025-11-11T15:59:58","modified_gmt":"2025-11-11T13:59:58","slug":"news-m","status":"publish","type":"page","link":"https:\/\/webs.uab.cat\/therCNS\/news-m\/","title":{"rendered":"News"},"content":{"rendered":"\n

Last 5 years<\/mark><\/h2>\n\n\n\n
<\/div>\n\n\n\n

2025<\/mark><\/h2>\n\n\n\n
\"\"<\/figure>
\n

Klotho Neurosciences Wins the 2025 BioTech Breakthrough<\/strong> ‘Cell Therapy Innovation of the Year’ Award<\/strong><\/a>. November 7th.<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/figure>
\n

The Irina Poate Association, from Romania, has donated \u20ac100,000 to the UAB’s microfunding campaign<\/strong><\/a> to investigate gene therapy to treat spastic paraplegia type 52 (SPG52). With this new contribution, the study carried out our research group has exceeded \u20ac750,000 in donations. November 11th.<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/figure>
\n

Invited Speaker<\/a><\/strong> at the First Klotho Conference <\/strong>in Los Angeles (US). September 15th.<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/figure>
\n

Presentation of the proceeds (\u20ac74,191.92) raised from the “La Lucha de Abril” solidarity race<\/strong> held on April 13 in Badalona, \u200b\u200borganized by the Mossos d’Esquadra<\/strong>. The entire proceeds will go toward funding the research project to develop a gene therapy for SPG52. May 14th.<\/p>\n<\/div><\/div>\n\n\n\n

2024<\/mark><\/h2>\n\n\n\n
\"\"<\/figure>
\n

Together with the Patient’s Association ANTIAN, our group starts a new project to develop a gene therapy strategy for the ADSL Deficiency. The starting event is the conference: “La raresa t\u00e9 dret a l’esperanc\u0327a. Per una ter\u00e0pia g\u00e8nica<\/strong>” together with a microfunding campaing<\/a>. January 25th. Centre Cultural Cambrils.<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/figure>
\n

ANEW Medical, spin-off de la UAB basada en los resultados de los grupos de la Dra Assumpci\u00f3 Bosch y Miguel Chill\u00f3n, entra al Nasdaq<\/a>. July 8th. <\/p>\n<\/div><\/div>\n\n\n\n

2023<\/mark><\/h2>\n\n\n\n
\"\"<\/figure>
\n

We participate in a Round Table<\/em>: “What are the latest technological trends, innovations and challenges in advanced therapies?<\/strong>“, in the Unconference 2023. CataloniaBio & HealthTech. October 3rd.
<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/figure>
\n

We participate in the Genera Podcast to disseminate hottest topics in biomedicine to the general public. The episodes are available on the main podcast distribution platforms such as: Google Podcast, Apple Podcast, Podimo and Spotify, with free and open access to the public. Interview<\/em>:”GENera | El presente de la medicina del futuro”.<\/strong> July 25th. Podcast<\/a><\/p>\n<\/div><\/div>\n\n\n\n

2022<\/mark><\/h2>\n\n\n\n
\"\"<\/figure>
\n

The UPV has attended to the First TECNIO Congress<\/strong> celebrated at the Universitat de Girona. The aim of the conference was to identify the current challenges facing our knowledge transfer ecosystem. October 19th. <\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/figure>
\n

Members of the Catalan Parliament and the Spanish Congress of Deputies visited some of the TECNIO Association<\/strong>\u2019s centres located (including ours -UPV-) on the Universitat Aut\u00f2noma de Barcelona\u2019s campus after having worked closely together on Catalonia\u2019s new law on science. September 16th.
<\/p>\n<\/div><\/div>\n\n\n\n

2021<\/mark><\/h2>\n\n\n\n
\"\"<\/figure>
\n

Together with Patient’s Association “El Gen Rebelde”, we start a new project to develop a gene therapy strategy for GNB1 Encephalopathy<\/strong> at the Vall d’Hebron research Institute (VHIR). The starting event is a microfunding campaing<\/a>. February 1st. <\/p>\n<\/div><\/div>\n\n\n\n

\n\n\n\n

Highlights. Previous Years<\/mark><\/h2>\n\n\n\n
\n

2020. May 18th<\/mark><\/mark><\/h3>\n\n\n\n

Together with Patient’s Association “La Lucha de Abril”, we start a new project to develop a gene therapy strategy for Spastic Paraplegia 52 (SPG52)<\/strong> at the Universitat Aut\u00f2noma de Barcelona. The starting event is a microfunding campaing<\/a>. May 18th.<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
\n

2019. March 15th<\/mark><\/mark><\/h3>\n\n\n\n

The UPV has obtained the TECNIO Quality Accreditation by ACCIO (Generalitat de Catalunya).
<\/strong>This acreditation certifies the high quality standards of services and procedures of the UPV. Currently there are only about 60 entities with this recognition.<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
\n

2018. August 23th<\/mark><\/mark><\/h3>\n\n\n\n

We are proud to announce that the UPV has recently obtained the ISO9001:2015 certification.<\/strong> ISO International Standards ensure that products and services are safe, reliable and have good quality. <\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
\n

2018. October 4th<\/mark><\/mark>. <\/mark><\/mark><\/h3>\n\n\n\n

Dr. Miguel Chill\u00f3n has received the I Transference Award<\/strong> by the Consell Social UAB due to his long record on technology transfer and valorization. Video-1<\/a> \/ Video-2<\/a><\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
\n

2017. December 12th<\/mark><\/h3>\n\n\n\n

Klogene Therapeutics, Inc. and Kogenix Therapeutics, Inc. today announced the merger of the two companies. The combined company, using the name Klogene<\/strong> (Boston, USA), is focused on Klotho, a naturally occurring human protein that has been shown to have potential therapeutic effects in neurodegenerative diseases. <\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
\n

2016. November 8th<\/mark><\/h3>\n\n\n\n

Dr. Miguel Chill\u00f3n gives the conference “El envejecimiento del cerebro y sus terapias”<\/strong> at the Centre de Cultura Contempor\u00e0nea de Barcelona (CCCB)<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
\n

2016. September 15th<\/mark><\/h3>\n\n\n\n

Dra. Assumpci\u00f3 Bosch and Dr. Miguel Chill\u00f3n have co-founded Kogenix Therapeutics<\/strong> (Boston, USA), a company’s gene therapy mainly focused on klotho gene therapy enabling medical industry to provide treatment for Alzheimer’s disease and gene related disease through this gene therapy. <\/p>\n<\/div>

\"\"<\/figure><\/div>\n","protected":false},"excerpt":{"rendered":"

Last 5 years 2025 Klotho Neurosciences Wins the 2025 BioTech Breakthrough ‘Cell Therapy Innovation of the Year’ Award. November 7th. The Irina Poate Association, from Romania, has donated \u20ac100,000 to the UAB’s microfunding campaign to investigate gene therapy to treat spastic paraplegia type 52 (SPG52). With this new contribution, the study carried out our research […]<\/p>\n","protected":false},"author":2848,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-161","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/users\/2848"}],"replies":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/comments?post=161"}],"version-history":[{"count":64,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/161\/revisions"}],"predecessor-version":[{"id":1312,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/161\/revisions\/1312"}],"wp:attachment":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/media?parent=161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}